L-Asparaginase encapsulated intact erythrocytes for treatment of acute lymphoblastic leukemia (ALL)

Journal of Controlled Release

Volumn 139, Issue 3, 2009, Pages 182-189

  Kwon, Young Min ^a,b,c   Chung, Hee Sun ^b   Moon, Cheol ^b   Yockman, James ^d   Park, Yoon Jeong ^e   Gitlin, Scott D ^f   David, Allan E ^g   Yang, Victor C ^a,b  

^a TIANJIN UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN   (United States)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e School of Dentistry   (South Korea)

^f UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^g Industrial Science and Technology Network Inc   (United States)

Author keywords

Acute lymphoblastic leukemia (ALL); Asparaginase therapy; Protein transduction domain (PTD) peptide; RBC encapsulation; Red blood cell (RBC) carriers

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA (ALL); ASPARAGINASE THERAPY; PROTEIN TRANSDUCTION DOMAIN (PTD) PEPTIDE; RBC ENCAPSULATION; RED BLOOD CELL (RBC) CARRIERS;

AMINES; BACTERIOPHAGES; BLOOD; CATALYST ACTIVITY; ENCAPSULATION; ENZYME ACTIVITY; ENZYMES; FLUORESCENCE; HEMOGLOBIN OXYGEN SATURATION; OXYGEN; PEPTIDES; SCANNING ELECTRON MICROSCOPY;

CELL MEMBRANES;

ASPARAGINASE; DRUG CARRIER; LOW MOLECULAR WEIGHT PROTAMINE; PROTAMINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ENCAPSULATION; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROCYTE; ERYTHROCYTE FRAGILITY; ERYTHROCYTE TRANSFUSION; HEMATOCRIT; MEAN CORPUSCULAR HEMOGLOBIN; MEAN CORPUSCULAR VOLUME; MOUSE; NONHUMAN; OXYGEN DISSOCIATION CURVE; PLASMA HALF LIFE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SURFACE PROPERTY; SURVIVAL RATE; SURVIVAL TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG COMPOUNDING; ENZYME STABILITY; ERYTHROCYTE TRANSFUSION; ERYTHROCYTES; FEASIBILITY STUDIES; HEMOLYSIS; MICE; MICE, INBRED DBA; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, SCANNING; MOLECULAR WEIGHT; OSMOTIC FRAGILITY; OVALBUMIN; PILOT PROJECTS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTAMINES; SHEEP;

EID: 70349322579     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.06.027     Document Type: Article

References (40)

1. http://www.cancer.gov/.
2. Pui C.H., and Evans W.E. Treatment of acute lymphoblastic leukemia. N. Engl. J. Med. 354 (2006) 66-178
3. Hill J.J., Roberts J., Loeb E., Khan A., MacLellan A., and Hill A.W. L-Asparaginase therapy for leukemia and other malignant neoplasms. Remission in human leukemia. J.A.M.A. 202 (1967) 882-888
4. Cooney D.A., and Handschumacher R.E. L-Asparaginase and L-asparagine metabolism. Annu. Rev. Pharmacol. 10 (1970) 421-440
5. Becker F.F., and Broome J.D. L-Asparaginase: inhibition of early mitosis in regenerating rat liver. Science 156 (1967) 1602-1603
6. Shepherd G.M. Hypersensitivity reactions to chemotherapeutic drugs. Clin. Rev. Allergy Immunol. 24 (2003) 253-262
7. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 3 (2003) 214-221
8. Graham M. Pegaspargase: a review of clinical studies. Adv. Drug Deliv. Rev. 55 (2003) 293-1302
9. Oettgen H.F., Tallal L., Tan C.C., and Murphy M.L. In: Grundman E., and Oettgen H.F. (Eds). Experimental and Clinical Effects of L-Asparaginase (1997), Springer, New York 219-243
10. Hamidi M., Zarrin A., Foroozesh M., and Mohammadi-Samani S. Applications of carrier erythrocytes in delivery of biopharmaceuticals. J. Control. Release 118 2 (2007) 145-160
11. Ataullakhanov F.I., Vitvitskii V.M., Zhabotinskii A.M., and Pichugin A.V. Permeability of human erythrocytes to asparagine. Biokhimiia 50 10 (1985) 1733-1737
12. Avramis V.I., Sencer S., and Periclou A.P. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99 6 (2002) 1986-1994
13. Ho D.H., Brown N.S., Yen A., et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab. Dispos. 14 (1986) 349-352
14. Benn-Bassat I., Bensch K.G., and Schrier S.L. Drug-induced erythrocyte membrane internalization. J. Clin. Invest. 51 7 (1985) 1833-1844
15. Millan C.G., Marinero M.L.S., Castaneda A.Z., and Lanao J.M. Drug, enzyme, and peptide delivery using erythrocyte as carriers. J. Control. Release 95 (2004) 27-49
16. Hamidi M., Tajerzadeh H., Dehpour A.R., Rouini M.R., and Ejtemaee-Mehr S. In vitro characterization of human intact erythrocytes loaded by enalaprilat. Drug Deliv. 8 (2001) 223-230
17. Ihler G.M., Glew R.H., and Schnure F.W. Enzyme loading of erythrocytes. Proc. Natl. Acad. Sci. U. S. A. 70 (1973) 2663-2666
18. Updike S.J., Wakamiya R.T., and Lightfoot Jr. E.N. Asparaginase entrapped in red blood cells: action and survival. Science 193 (1976) 681-683
19. Garin M.I., Lopez R.M., Sanz S., Pinilla M., and Luque J. Erythrocytes as carriers for recombinant human erythropoietin. Pharm. Res. 13 6 (1996) 869-874
20. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
21. Joliot A., Pernelle C., Deagostini-Bazin H., and Prochiantz A. Antennapedia homeobox peptide regulates neutral morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 1864-1868
22. Elliott G., and O'Hare P. Intercellular trafficking and protein delivery by a hyrpesvirus structural protein. Cell 88 (1997) 223-233
23. Suzuki T., Futaki S., Niwa M., Tanaka S., Ueda K., and Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277 (2002) 2437-2443
24. Chang L.C., Lee H.F., Yang Z., and Yang V.C. Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (I): preparation and characterization. AAPS PharmSci 3 3 (2001) E17
25. Park Y.J., Chang L.C., Liang J.F., Moon C., Chung C.P., and Yang C. Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. Faseb J. 19 11 (2005) 1555-1557
26. Dietz G.P., and Bahr M. Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell Neurosci. 27 2 (2004) 85-131
27. Nori A., Jensen K.D., Tijerina M., Kopeková P., and Kopeek J. Subcellular trafficking of HPMA copolymer-Tat conjugates in human ovarian carcinoma cells. J. Control. Release 91 (2003) 53-59
28. Ho P.P., Milikin E.B., Bobbitt J.L., et al. Crystalline L-asparaginase from Escherichia coli B. I. Purification and chemical characterization. J. Biol. Chem. 245 14 (1970) 3708-3715
29. American Hospital Formulary Service (AHFS) Drug Information: Asparaginase (2001), American Society of Health-System Pharmacists, Bethesda, MD
30. Kravtzoff R., Ropars C., Laguerre M., Muh J.P., and Chassainge M. Erythrocytes as carriers for L-asparaginase. Methodological and mouse in vivo studies. J. Pharm. Pharmacol. 42 (1990) 473-476
31. Chalmers R.A. Comparison and potential of hypo-osmotic and iso-osmotic erythrocyte ghosts and carrier erythrocytes as drug and enzyme carriers. Bibl. Haematol. 51 (1985) 15-24
32. Magnani M., Fazi A., Magnani F., Rossi L., and Mancini U. Methanol detoxification by enzyme-loaded erythrocytes. Biotechnol. Appl. Biochem. 18 (1993) 217-226
33. Berg J.M., Tymoczko J.L., and Stryer L. Biochemistry. 6th ed (1988), Freeman and Company, New York, NY
34. Chiarantini L., Johnson J., and Deloach J.R. Optimized recirculation survival of mouse carrier erythrocytes. Blood Cells, 17 (1991) 607-617
35. Kravtzoff R., Desbois I., and Lamagnere J.P. Improved pharmacodynamics of L-asparaginase-loaded in human red blood cells. Eur. J. Clin. Pharmacol. 49 (1996) 465-470
36. Kodera Y., Sekine T., and Yasukohchi T. Stabilization of L-asparaginase modified with comb-shaped poly(ethylene glycol) derivatives, in vivo and in vitro. Bioconjug. Chem. 5 (1994) 283-286
37. Y.T. Li, Y.M. Kwon, G.J. Spangrude, J.F. Liang, H. Chung, Y.J. Park, and V.C. Yang, Preliminary In Vivo Evaluation of the PTD-Modified ATTEMPTS Approach in Enhancing Asparaginase Therapy J. Biomed. Mater. Res A. (accepted for publication; DOI 10.1002/jbm.a.32204).
38. Kwon Y.M., Li Y.T., Liang J.F., Park Y.J., Chang L.C., and Yang V.C. PTD-modified ATTEMPTS system for enhanced asparaginase therapy: a proof-of-concept investigation. J. Control. Release 130 (2008) 252-258
39. Alpar H.O., and Lewis D.A. Therapeutic efficacy of asparaginase encapsulated in intact erythrocytes. Biochem. Pharmacol. 34 (1985) 257-261
40. Moraga F., Monge C., Riquelme R., and Llanos A.J. Fetal and maternal blood oxygen affinity: a comparative study in llamas and sheep. Comp. Biochem. Physiol. 115A (1996) 111-115